$0.991
+0.007 (+0.75%)Zum Schluss
LUCD-News
LUCD-Events
Lucid Reports Q2 Revenue of $1.5M, Exceeds Expectations
Reports Q2 revenue $1.5M, consensus $1.43M. "Lucid's commercial momentum strengthened throughout the second quarter and in recent weeks," said CEO Lishan Aklog. "We continue to advance multiple commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard. We secured positive commercial coverage policies, accelerated engagement with the VA and major health systems, and demonstrated the long-term economic value of EsoGuard testing. Progress across these initiatives positions Lucid to capitalize on EsoGuard's significant clinical and commercial opportunity, while increasing the company's visibility and thereby expanding opportunities for broader strategic engagement."
Lucid Diagnostics' EsoGuard Test Recognized by Concert Coverage Policy
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient evidence in published guidelines and peer-reviewed literature to definitively demonstrate improved health outcomes, and considers Lucid's EsoGuard Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology screening criteria.
Lucid Q1 Revenue at $1.26M, Below Consensus
Reports Q1 revenue $1.26M, consensus $1.38M. "Securing Medicare coverage remains our most important pending milestone, and our confidence in a positive outcome has not wavered," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We continue to build commercial momentum for EsoGuard by generating consistent demand, progressing our Medicare and VA targeting efforts, and expanding engagement with health systems and commercial payors. Together with our strengthened balance sheet, these initiatives have us well-positioned to convert EsoGuard demand to revenue and further accelerate commercialization as Medicare and other key reimbursement milestones are achieved."
Lucid Diagnostics Prices 18M Share Offering at $1.00 Each
Lucid Diagnostics announced the pricing of an underwritten registered direct offering of 18M common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $18M. The offering is expected to close on or about April 24, subject to customary closing conditions. Canaccord Genuity and BTIG are acting as joint bookrunners for the offering.
Lucid Reports Q4 Revenue of $1.5M
Reports Q4 revenue $1.5M vs. $1.2B last year. Lucid had cash and cash equivalents of $34.7M as of December 31, 2025 vs. $22.4M as of December 31, 2024. "Throughout 2025, we established a strong commercial foundation for EsoGuard, demonstrating that we can consistently generate and sustain demand, drive physician adoption, and engage effectively with both health systems and commercial payors," said CEO Lishan Aklog. "As we move into 2026, our focus is on building on that foundation by converting demand into revenue, with priorities including deepening our relationship with the VA, expanding adoption across health systems, advancing coverage with commercial payors, and securing Medicare coverage, which we still expect in the near-term."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.